Furthermore, in light of the promising preclinical results for the combination of BRAF inhibitors with MAPK inhibitors in CRC (Ahronian et al., 2015; Ursem, Atreya, & Van Loon, 2018), it is compelling to consider the use of GDF15 inhibitors, such as AV‐380 (Aveo) with anti‐BRAF therapies in the future (Of note, the HT29 cell line carries mutant BRAF V600E). Here, GDF15 is linked to colorectal carcinoma.